550 related articles for article (PubMed ID: 28110457)
1. Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways.
Liebig H; Günther G; Kolb M; Mozet C; Boehm A; Dietz A; Wichmann G
Cancer Chemother Pharmacol; 2017 Feb; 79(2):411-420. PubMed ID: 28110457
[TBL] [Abstract][Full Text] [Related]
2. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
[TBL] [Abstract][Full Text] [Related]
3. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
4. Hedgehog targeting by cyclopamine suppresses head and neck squamous cell carcinoma and enhances chemotherapeutic effects.
Mozet C; Stoehr M; Dimitrova K; Dietz A; Wichmann G
Anticancer Res; 2013 Jun; 33(6):2415-24. PubMed ID: 23749890
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
[TBL] [Abstract][Full Text] [Related]
6. Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics.
Stoehr M; Mozet C; Boehm A; Aigner A; Dietz A; Wichmann G
Cancer Chemother Pharmacol; 2014 Apr; 73(4):827-37. PubMed ID: 24562588
[TBL] [Abstract][Full Text] [Related]
7. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
8. Cilengitide and Cetuximab Reduce Cytokine Production and Colony Formation of Head and Neck Squamous Cell Carcinoma Cells
Wichmann G; Cedra S; Schlegel D; Kolb M; Wiegand S; Boehm A; Hofer M; Dietz A
Anticancer Res; 2017 Feb; 37(2):521-527. PubMed ID: 28179297
[TBL] [Abstract][Full Text] [Related]
9. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
[TBL] [Abstract][Full Text] [Related]
10. Stimulation by Monocyte Chemoattractant Protein-1 Modulates the Ex-vivo Colony Formation by Head and Neck Squamous Cell Carcinoma Cells.
Wichmann G; Körner C; Boehm A; Mozet C; Dietz A
Anticancer Res; 2015 Jul; 35(7):3917-24. PubMed ID: 26124338
[TBL] [Abstract][Full Text] [Related]
11. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
[TBL] [Abstract][Full Text] [Related]
12. Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer.
Hsu DS; Hwang WL; Yuh CH; Chu CH; Ho YH; Chen PB; Lin HS; Lin HK; Wu SP; Lin CY; Hsu WH; Lan HY; Wang HJ; Tai SK; Hung MC; Yang MH
Clin Cancer Res; 2017 Aug; 23(15):4388-4401. PubMed ID: 28196873
[No Abstract] [Full Text] [Related]
13. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
15. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
16. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
Boeckx C; Van den Bossche J; De Pauw I; Peeters M; Lardon F; Baay M; Wouters A
BMC Res Notes; 2015 Jun; 8():203. PubMed ID: 26032726
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
18. Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
Swick AD; Prabakaran PJ; Miller MC; Javaid AM; Fisher MM; Sampene E; Ong IM; Hu R; Iida M; Nickel KP; Bruce JY; Wheeler DL; Kimple RJ
Mol Cancer Ther; 2017 Jul; 16(7):1257-1268. PubMed ID: 28446642
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.
Lattanzio L; Milano G; Monteverde M; Tonissi F; Vivenza D; Merlano M; Lo Nigro C
Anticancer Drugs; 2016 Jul; 27(6):533-9. PubMed ID: 26982238
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M
Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
